Strategic Initiative
Slingshot members are tracking this corporate initiative:
Novartis (NVS) Out-Licenses U.S Rights to Three Treatments for Chronic Obstructive Pulmonary Disease (COPD) to Sunovion Pharmaceuticals
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
Sunovion Pharmaceuticals |
|
|
|
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 21, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2018
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
U.s Rights, Three Treatments, Chronic Obstructive Pulmonary Disease, Copd, Utibron Neohaler, Seebri Neohaler, Arcapta Neohaler
